ArrayExpress Uploaderarrayexpress_sidhuman53Patient 4baselinebaseline53Patient 4BETAFERON3 month of BETAFERON53Patient 4BETAFERON12 month of BETAFERON53Patient 4BETAFERON24 month of BETAFERON52Patient 13baselinebaseline52Patient 13REBIF3 month of REBIF52Patient 13REBIF12 month of REBIF52Patient 13REBIF24 month of REBIF50Patient 999baselinebaseline50Patient 999BETAFERON3 month of BETAFERON50Patient 999BETAFERON12 month of BETAFERON50Patient 999BETAFERON24 month of BETAFERON50Patient 998baselinebaseline50Patient 998BETAFERON3 month of BETAFERON50Patient 998BETAFERON12 month of BETAFERON50Patient 998BETAFERON24 month of BETAFERON33Patient 108baselinebaseline33Patient 108BETAFERON3 month of BETAFERON33Patient 108BETAFERON12 month of BETAFERON33Patient 108BETAFERON24 month of BETAFERON35Patient 112baselinebaseline35Patient 112REBIF3 month of REBIF35Patient 112REBIF12 month of REBIF35Patient 112REBIF24 month of REBIF36Patient 113baselinebaseline36Patient 113REBIF3 month of REBIF36Patient 113REBIF12 month of REBIF36Patient 113REBIF24 month of REBIF36Patient 116baselinebaseline36Patient 116REBIF3 month of REBIF36Patient 116REBIF12 month of REBIF36Patient 116REBIF24 month of REBIF389304We aimed to identify specific biomarkers of IFN-beta bioactivity in order to compare their gene expression induction by type I IFNs with...E-GEOD-26104/profile/8773/arrayexpressuploader432Dec.12, 2014Falsesearch-for-specific-biomarkers-of-ifn-beta-bioactiE-GEOD-26104_A-AFFY-44Search for specific biomarkers of IFN-beta bioactivity in patients with MSSep.15, 2014We aimed to identify specific biomarkers of IFN-beta bioactivity in order to compare their gene expression induction by type I IFNs with the MxA, and to investigate their potential role in MS pathogenesis. Gene expression microarrays were performed in PBMC from MS patients who developed neutralizing antibodies (NAB) to IFN-beta. Nine genes followed patterns in gene expression over time similar to the MX1 and were selected for further experiments: IFI6, IFI27, IFI44L, IFIT1, HERC5, LY6E, RSAD2, SIGLEC1, and USP18. In vitro experiments revealed specific induction of selected biomarkers by IFN-beta but not IFN-gamma, and several markers, in particular USP18 and HERC5, were significantly induced at lower IFN-beta concentrations and more selective than the MX1 as biomarkers of IFN-beta bioactivity. In addition, USP18 expression was deficient in MS patients compared with healthy controls (p=0.0004). We propose specific biomarkers that may be considered in addition to the MxA to evaluate IFN-beta bioactivity, and to further explore their implication in MS pathogenesis. Number of samples: 32. We analyzed PBMC from 8 patients at baseline and after 3, 12 and 24 months of IFN-beta treatmenthttp://www.ebi.ac.uk/arrayexpress/experiments/E-GEOD-26104http://www.ebi.ac.uk/arrayexpress/experiments/E-GEOD-26104/samples/